[{"id":"e96ac04f-d494-4797-b71d-2048e4719923","acronym":"","url":"https://clinicaltrials.gov/study/NCT03318900","created_at":"2021-01-18T16:23:25.179Z","updated_at":"2024-07-02T16:35:05.191Z","phase":"Phase 1/2","brief_title":"T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer","source_id_and_acronym":"NCT03318900","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-A • PRAME • COL6A3","pipe":" | ","alterations":" PRAME expression","tags":["HLA-A • PRAME • COL6A3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PRAME expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Proleukin (aldesleukin) • utomilumab (PF-05082566) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 07/16/2018","start_date":" 07/16/2018","primary_txt":" Primary completion: 12/20/2023","primary_completion_date":" 12/20/2023","study_txt":" Completion: 12/20/2023","study_completion_date":" 12/20/2023","last_update_posted":"2024-05-08"},{"id":"0444b2f1-748a-4185-94b9-0f9f411e1ec7","acronym":"","url":"https://clinicaltrials.gov/study/NCT01149343","created_at":"2021-01-18T04:34:31.399Z","updated_at":"2024-07-02T16:36:38.411Z","phase":"Phase 1","brief_title":"Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer","source_id_and_acronym":"NCT01149343","lead_sponsor":"GlaxoSmithKline","biomarkers":" PRAME","pipe":" | ","alterations":" PRAME expression","tags":["PRAME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PRAME expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GSK2302025A • GSK2302032A"],"overall_status":"Completed","enrollment":" Enrollment 107","initiation":"Initiation: 07/02/2010","start_date":" 07/02/2010","primary_txt":" Primary completion: 02/11/2014","primary_completion_date":" 02/11/2014","study_txt":" Completion: 12/19/2016","study_completion_date":" 12/19/2016","last_update_posted":"2020-11-20"},{"id":"cd12a940-db2a-47ad-a522-ff5a12bd7679","acronym":"PEARL","url":"https://clinicaltrials.gov/study/NCT01853878","created_at":"2021-01-18T08:16:48.190Z","updated_at":"2024-07-02T16:36:56.168Z","phase":"Phase 2","brief_title":"A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor","source_id_and_acronym":"NCT01853878 - PEARL","lead_sponsor":"GlaxoSmithKline","biomarkers":" PRAME","pipe":" | ","alterations":" PRAME expression","tags":["PRAME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PRAME expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GSK2302032A"],"overall_status":"Completed","enrollment":" Enrollment 137","initiation":"Initiation: 06/12/2013","start_date":" 06/12/2013","primary_txt":" Primary completion: 08/24/2016","primary_completion_date":" 08/24/2016","study_txt":" Completion: 08/24/2016","study_completion_date":" 08/24/2016","last_update_posted":"2019-08-28"}]